End of the HEV outbreak in Namibia





On 2 March 2022 the Namibians government declared an end to the HEV outbreak.  The 4-year long outbreak affected 13 of the 14 political regions mainly in informal settlements and areas with poor hygiene and sanitation.

A cumulative total  of 8 092 Hepatitis E cases were reported nationally as of 30 January 2022, of which 2 124 (26.2%) were laboratory confirmed, 4 738 (58.6%) cases were epidemiologically linked, and 1 230 (15.2%) cases were suspected cases.   A total of 66 HEV deaths have been reported nationally (Case Fatality Rate (CFR) of 0.8%). Among the 66 deaths, 27 are maternal deaths, representing 41% of the total HEV deaths and 6.2% of all the reported maternal HEV cases.

WHO played a strong convening and coordinating role since the onset of the HEV outbreak and mobilized other UN agencies, development partners, regional and local authorities, and civil society organizations to rally behind the government to control the outbreak.  The organization further invested over N$ 6.5 million and technical support which enhanced case management, surveillance, laboratory services, infection prevention and control, risk communication and community engagement, water, sanitation, and hygiene.  WHO received additional support of N$ 4 million from the Government of Japan which strengthened the support WHO provided to the  government to control the HEP E Virus outbreak.

Source https://www.afro.who.int/countries/namibia/news/end-hepatitis-e-virus-outbreak-namibia







More of this tag...

Public health

Hepatitis E virus in the Kathmandu Valley of Nepal
Published by Nishan Katuwal
HEV is estimated to cause approximately 20 million new infections annually, leading to around 3.3 million symptomatic cases and 70,000 deaths. However, these figures may be underestimated due to limited surveillance capacity and suboptimal access to

Public health

Results from a large effectiveness trial evaluating the protection of pregnant women by HEV vaccine in Bangladesh
Published by Susanne Dudman, Asma Aziz
We conducted a large phase 4, double-blind, cluster-randomised trial in 67 villages in Matlab, Bangladesh, and hereby share some of our results. Between 2017 and2021, 19 460 participants were randomised to receive HEV239, a recombinant hepatitis E vi






EVENTS

2025-01-18

International Joint Meeting on Viral Infections of the Liver and the Heart (2025)
Day two of this symposium will place a special emphasis on Hepatitis E — a virus that, despite being the most common cause of viral hepatitis, offers a valuable opportunity for further research and understanding. Venue: Cantinerie Berlin Gustav-Meyer-Allee 25 13355 Berlin, Germany. Organisers: Prof. Dr. Jens Kurreck, Dr. rer. nat. Daniel Todt, Prof. Dr. med. Heiner Wedemeyer, More information: Medizinische Hochschule Hannover : International DFG/DZIF Joint Meeting on Viral Infections of the Liver and the Heart (mhh.de)

GHEP offers free membership for your better connection with the hepatitis E community